James O'Reilly
University of Cincinnati - CC
James O'Reilly is a Volunteer Professor of Law at University of Cincinnati, where he has counseled large and small drug, biotech, device and food firms since becoming a full time professor in 1998. Prof. O’Reilly’s 31 books and 137 articles have been widely cited, and as an FDA expert over many years he has led trade association and NGO projects dealing with complex FDA approval, recall and enforcement issues. His book on crisis management and his work on product warnings in text and articles have been widely followed. Prof. O’Reilly’s federal consulting assignments for FTC Chairman's office, EPA, Congressional Office of Compliance and Administration Conference and numerous expert witness and consulting roles have given broad experience on FDA and tort liability issues. He previously worked at The Procter & Gamble Company as Associate General Counsel for 24 years. As the Company's principal regulatory counsel, he worked closely with internal clients and with industry coalitions on EPA, FDA, regulatory agency and Congressional matters. (This is me - Update Profile)
| 1998 - present | Volunteer Professor of Law University of Cincinnati - CC |
|---|---|
| 1974 - 1998 | Associate General Counsel The Procter & Gamble Company |
GLG Study Groups with James O'Reilly(?)
| Study Group Name | Members |
|---|---|
| Pharmaceutical Regulation and FDA Experts: Lawyers | 49 |
| Medical Device Experts | 257 |
GLG NewsSM
Analyses by James O'Reilly(?)
Product liability exposure of new materials makers can be severe, especially with fatal consequences of failures Internal memos re product problems can shoot company in the foot; prudent firms have a plan for controlling open-ended speculative memos in an instant-message environment Major PR and govt....
Recent reports by a federal study panel, addressed in stories in the NY Times and other sources, highlight one more gap between expectations and reality in the resource-starved federal safety net for consumers. Much less is being done to oversee Gene Test kits than consumers may expect; eventually there...
"Son of Asbestos" claims may sound extreme; but the lead paint makers would be prudent to collectively negotiate and fund a 50-state settlement that follow the tobacco companies' model and avoids the bankruptcy model of the asbestos-using firms. Lead injury awareness has increased and demands for public...
GLG InstituteSM Seminars with James O'Reilly(?)
Recent Seminars
Request a project with James O'Reilly
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

